Clinical Trial: Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: Long-term Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus

Brief Summary: The purpose of this study is to investigate the long-term safety, tolerability and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN). In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included.

Detailed Summary:
Sponsor: Merz Pharmaceuticals GmbH

Current Primary Outcome: Long-term safety, Visual acuity [ Time Frame: Baseline, week 4, month 3, 6, 9, 12, 18, 24, 30, 36 and follow-up ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Merz Pharmaceuticals GmbH

Dates:
Date Received: November 27, 2008
Date Started: May 2009
Date Completion:
Last Updated: June 30, 2010
Last Verified: June 2010